Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05913427
Other study ID # ASSTBS-FARONCO- PESETA-20
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date June 8, 2022
Est. completion date June 8, 2027

Study information

Verified date January 2023
Source Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Contact Aldo Roccaro
Phone +390303996851
Email coordinamento.ricerca@asst-spedalicivili.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective randomized, double blind, placebo controlled phase II study planned in patients with advanced ACC. The study will be conducted at ASST Spedali Civili Hospital and University of Brescia in Brescia.


Description:

As no effective second-line therapies are available for patients with disease progression to EDPM, including modern molecular target therapies and immunotherapy, it is reasonable to expect that no newer drugs or combination regimens will be able to replace EDPM in the next 5 years. Since EDP-M is destined to remain the standard first line therapy, research strategies aimed to improve the efficacy of this regimen are of relevance. In this study, investigators will address the hypotheses that progesterone has a synergistic and/or additive effect to EDP-M in inducing cytotoxicity in ACC cells in vitro and the antineoplastic activity of EDP-M in locally advanced/metastatic ACC patients could be improved by the addition of megestrol acetate.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date June 8, 2027
Est. primary completion date June 8, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically confirmed diagnosis of ACC - Locally advanced or metastatic disease not amenable to radical surgery resection - ECOG performance status 0-2 - Effective contraception - Life expectancy > 3 months - Age > 18 years - Adequate bone marrow reserve (neutrophils >1,000/mm3 and/or platelets >80,000/mm3) and organ function (including renal, liver and cardiac function) - Be able to comply with the protocol procedures and provide written informed consent. Exclusion Criteria: - History of recent or active prior malignancy, except for cured non-melanoma skin cancer, cured in situ cervical carcinoma, breast ductal carcinoma in situ, or other treated malignancies where there has been no evidence of disease for at least 2 years - Renal insufficiency (estimated glomerular filtration rate [GFR]<50 mL/min/1.73 m2) or significant liver insufficiency (serum bilirubin>2 times the upper normal range and/or serum alanine aminotransferase [ALT] or aspartate aminotransferase [AST]>3 times the upper normal range). GFRs will be calculated according to the validated formula (MDRD) - Pregnancy or breast feeding - Congestive heart failure (ejection fraction<45%) - Preexisting grade 2 peripheral neuropathy - Previous or current treatment with mitotane or other antineoplastic drugs for ACC - Previous radiotherapy for ACC - Any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration or that, in the judgment of the investigator, would make the patient inappropriate for entry into this study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Etoposide, doxorubicin, cisplatin and Mitotane plus Megestrol Acetate 160 MG
EDP will be administered at the following doses: doxorubicin 40 mg/m2 on day 1, etoposide 100 mg/m2 days 2-4, cisplatin 40 mg/m2 days 3-4, every 28 days. Megestrol acetate will be prepared and packaged by the authorized external contract development and manufacturing organization (CDMO) Doppel Farmaceutici s.r.l. (Cortemaggiore, PC), that, according to the GMP and applicable law (FU XII ed) will also prepare the related placebo, in accordance with GMP (annex 13) and applicable law (FU XII ed.).
Etoposide, doxorubicin, cisplatin and Mitotane plus Placebo
EDP will be administered at the following doses: doxorubicin 40 mg/m2 on day 1, etoposide 100 mg/m2 days 2-4, cisplatin 40 mg/m2 days 3-4, every 28 days. Placebo 160 mg tablets will be developed by the CDMO to have the same appearance and taste as the tablet containing the active drug.

Locations

Country Name City State
Italy Alfredo Berruti Brescia

Sponsors (1)

Lead Sponsor Collaborator
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Country where clinical trial is conducted

Italy, 

References & Publications (5)

Fassnacht M, Assie G, Baudin E, Eisenhofer G, de la Fouchardiere C, Haak HR, de Krijger R, Porpiglia F, Terzolo M, Berruti A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Adrenocortical carcinomas and malignant phaeochromocy — View Citation

Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B, Sorbye H, Torpy DJ, Stepan V, Schteingart DE, Arlt W, Kroiss M, Leboulleux S, Sperone P, Sundin A, Hermsen I, Hahner S, Willenberg HS, Tabar — View Citation

Fiorentini C, Fragni M, Perego P, Vezzoli S, Bonini SA, Tortoreto M, Galli D, Claps M, Tiberio GA, Terzolo M, Missale C, Memo M, Procopio G, Zaffaroni N, Berruti A, Sigala S. Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocorti — View Citation

Fragni M, Fiorentini C, Rossini E, Fisogni S, Vezzoli S, Bonini SA, Dalmiglio C, Grisanti S, Tiberio GAM, Claps M, Cosentini D, Salvi V, Bosisio D, Terzolo M, Missale C, Facchetti F, Memo M, Berruti A, Sigala S. In vitro antitumor activity of progesterone — View Citation

Rossini E, Tamburello M, Abate A, Beretta S, Fragni M, Cominelli M, Cosentini D, Hantel C, Bono F, Grisanti S, Poliani PL, Tiberio GAM, Memo M, Sigala S, Berruti A. Cytotoxic Effect of Progesterone, Tamoxifen and Their Combination in Experimental Cell Mod — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of the activity of the combination regimen (EDP-M plus progesterone (EDP-MP) versus EDP-M plus placebo) in advanced/ metastatic patients with ACC. Comparison of proportion of patients attaining an Objective Response (Objective Response Rate, ORR), evaluated by RECIST criteria between the 2 treatment arms. 18 months
Secondary Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC; Changes in serum cortisol from baseline in the two treatment arms; 18 months
Secondary Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC; Changes in serum UFC from baseline in the two treatment arms; 18 months
Secondary Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC; Changes in serum salivary cortisol from baseline in the two treatment arms; 18 months
Secondary Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC; Changes in ACTH from baseline in the two treatment arms; 18 months
Secondary Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC; Changes in serum 11-deoxycortisol from baseline in the two treatment arms; 18 months
Secondary Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC; Changes in serum aldosterone from baseline in the two treatment arms; 18 months
Secondary Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC; Changes in serum PRA from baseline in the two treatment arms; 18 months
Secondary Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC; Changes in serum androstenedione from baseline in the two treatment arms; 18 months
Secondary Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC; Changes in serum DHEA-S from baseline in the two treatment arms; 18 months
Secondary Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC; Changes in serum progesterone from baseline in the two treatment arms; 18 months
Secondary Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC; Changes in serum total testosterone from baseline in the two treatment arms; 18 months
See also
  Status Clinical Trial Phase
Completed NCT04373265 - Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol) Phase 1
Recruiting NCT06050057 - Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy
Recruiting NCT06066333 - Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma Phase 2
Recruiting NCT03127774 - Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma Phase 2
Completed NCT01048892 - Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features Phase 1
Recruiting NCT00457587 - Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma
Recruiting NCT00669266 - Adrenal Tumors - Pathogenesis and Therapy
Recruiting NCT05999292 - Phase 1 Study of 68Ga-R8760 Phase 1
Completed NCT05361083 - First-in-human Evaluation of [18F]CETO Early Phase 1
Recruiting NCT05660889 - Adrenal Vein Sampling as a Tool to Identify Biomarkers That Aid the Diagnosis of Adrenocortical Carcinoma
Completed NCT00003038 - Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors Phase 1
Enrolling by invitation NCT03474237 - A Prospective Cohort Study for Patients With Adrenal Diseases
Recruiting NCT04119024 - Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors Phase 1
Enrolling by invitation NCT05036434 - Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma Phase 2
Terminated NCT05012397 - Milademetan in Advanced/Metastatic Solid Tumors Phase 2
Not yet recruiting NCT06333314 - Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI Phase 2
Withdrawn NCT00469469 - Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma Phase 2
Completed NCT00002608 - Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Phase 2
Not yet recruiting NCT05839886 - The Adverse Event of Mitotane Therapy in Patients With Adrenocortical Carcinoma
Recruiting NCT05634577 - A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma Phase 2